Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CGT1815
- Development stage
- Preclinical
- Lead developer
- Cogent Biosciences
- Modality
- Small Molecules
01
Overview
CGT1815 is a selective, small molecule pan-KRAS(ON) inhibitor being developed by Cogent Biosciences for the treatment of solid tumors harboring KRAS mutations, including colorectal cancer, non-small cell lung cancer, and pancreatic cancer. It is designed as a prodrug of CGT1263, a potent KRAS(ON/OFF) inhibitor that binds to the Switch II pocket of the KRAS protein. CGT1815 demonstrates high selectivity for mutant KRAS over HRAS and NRAS and has shown sub-nanomolar potency across various KRAS mutant cell lines in preclinical studies. The compound is currently undergoing IND-enabling studies with an Investigational New Drug application planned for 2026.
02
Targets
Beyond the preview
Go deeper on CGT1815.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CGT1815.